{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:26:48Z","timestamp":1787016408209,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1124\/jpet.117.241596","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T20:40:24Z","timestamp":1498768824000},"page":"489-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468"],"prefix":"10.1016","volume":"362","author":[{"given":"Alexander","family":"Treiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"de Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Boss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"von Raumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Schindelholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Muehlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Jenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.241596_bib1","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1016\/j.bmcl.2008.09.079","article-title":"N-Glycine-sulfonamides as potent dual orexin 1\/orexin 2 receptor antagonists","volume":"18","author":"Aissaoui","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.241596_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/op1002853","article-title":"The first large-scale synthesis of MK-4305: a dual orexin receptor antagonist for the treatment of sleep disorder","volume":"15","author":"Baxter","year":"2011","journal-title":"Org Process Res Dev"},{"key":"10.1124\/jpet.117.241596_bib3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/0269881111408954","article-title":"Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist","volume":"26","author":"Bettica","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.117.241596_bib4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/npp.2011.310","article-title":"Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia","volume":"37","author":"Bettica","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.241596_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia","volume":"354","author":"Bonaventure","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.241596_bib6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/jpet.114.220392","article-title":"A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects","volume":"352","author":"Bonaventure","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.241596_bib7","unstructured":"Boss C, Brotschi C, Gude M, Heidmann B, Sifferlen T, Von Raumer M, and Williams JT (2015a) inventors, Idorsia Pharmaceuticals Ltd, assignee. Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists. Publ. no. WO\/2015\/083070. International application number: PCT\/IB2014\/066508. 2015 Nov 6."},{"key":"10.1124\/jpet.117.241596_bib8","unstructured":"Boss C, Brotschi C, Gude M, Heidmann B, Sifferlen T, and Williams JT (2013) inventors, Idorsia Pharmaceuticals Ltd, assignee. Benzimidazole-proline derivatives. Publ. no. WO\/2013\/182972. International application number: PCT\/IB2013\/054567. 2013 Dec 12."},{"key":"10.1124\/jpet.117.241596_bib9","unstructured":"Boss C, Roch C, Brotschi C, Gude M, Heidmann B, Jenck F, Sifferlen T, Steiner MA, and Williams JT (2015b) inventors, Idorsia Pharmaceuticals Ltd, assignee. Use of benzimidazole-proline derivatives. Publ. no. WO\/2015\/083094. International appl. no. PCT\/IB2014\/066548. 2015 Nov 6."},{"key":"10.1124\/jpet.117.241596_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2533\/chimia.2008.974","article-title":"Orexin receptor antagonism: a new principle in neuroscience","volume":"62","author":"Boss","year":"2008","journal-title":"Chimia (Aarau)"},{"key":"10.1124\/jpet.117.241596_bib11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cmdc.201402258","article-title":"Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1\/orexin 2 receptor antagonist","volume":"9","author":"Boss","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.117.241596_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2008.12.018","article-title":"The brain hypocretins and their receptors: mediators of allostatic arousal","volume":"9","author":"Carter","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.117.241596_bib13","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.117.241596_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/ijcp.12568","article-title":"Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"Citrome","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1124\/jpet.117.241596_bib16","doi-asserted-by":"crossref","first-page":"pyw022","DOI":"10.1093\/ijnp\/pyw022","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","volume":"19","author":"Connor","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.117.241596_bib17","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.241596_bib18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3109\/00498254.2015.1129565","article-title":"In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans","volume":"46","author":"Cui","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.117.241596_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40262-015-0322-y","article-title":"Physiologically-based pharmacokinetic modeling of macitentan: prediction of drug-drug interactions","volume":"55","author":"de Kanter","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.117.241596_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.241596_bib21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/jps.23916","article-title":"Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem","volume":"103","author":"Dingemanse","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.117.241596_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnins.2014.00028","article-title":"Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism","volume":"8","author":"Dugovic","year":"2014","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.117.241596_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1532-5415.2010.03229.x","article-title":"Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: a randomized placebo-controlled trial","volume":"59","author":"Frey","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/jpet.117.241596_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","article-title":"Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits","volume":"331","author":"Glass","year":"2005","journal-title":"BMJ"},{"key":"10.1124\/jpet.117.241596_bib26","doi-asserted-by":"crossref","first-page":"27147","DOI":"10.1038\/srep27147","article-title":"Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man","volume":"6","author":"Gotter","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.117.241596_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci"},{"key":"10.1124\/jpet.117.241596_bib28","doi-asserted-by":"crossref","first-page":"e16406","DOI":"10.1371\/journal.pone.0016406","article-title":"Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists","volume":"6","author":"Gozzi","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/jpet.117.241596_bib29","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cmdc.201600175","article-title":"Discovery of highly potent dual orexin receptor antagonists via a scaffold-hopping approach","volume":"11","author":"Heidmann","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.117.241596_bib30","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1124\/jpet.117.241596_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000335367","article-title":"Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects","volume":"89","author":"Hoch","year":"2012","journal-title":"Pharmacology"},{"key":"10.1124\/jpet.117.241596_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0269881112448946","article-title":"Orexin receptor antagonism: an ascending multiple-dose study with almorexant","volume":"26","author":"Hoever","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.117.241596_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.117.241596_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/7854_2016_47","article-title":"Orexin OX2 receptor antagonists as sleep aids","volume":"33","author":"Jacobson","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1124\/jpet.117.241596_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/jpet.117.241596_bib36","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/npp.2012.38","article-title":"Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia","volume":"37","author":"Johnson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.241596_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1208\/s12248-009-9088-1","article-title":"Modelling and PBPK simulation in drug discovery","volume":"11","author":"Jones","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/jpet.117.241596_bib39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nn.3810","article-title":"Motivational activation: a unifying hypothesis of orexin\/hypocretin function","volume":"17","author":"Mahler","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.117.241596_bib40","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1021\/ol3014123","article-title":"Enantioselective synthesis of a dual orexin receptor antagonist","volume":"14","author":"Mangion","year":"2012","journal-title":"Org Lett"},{"key":"10.1124\/jpet.117.241596_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnins.2014.00026","article-title":"Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use","volume":"8","author":"Merlo Pich","year":"2014","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.117.241596_bib42","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.117.241596_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/108705719900400506","article-title":"Analysis of apparent noncompetitive responses to competitive H(1)-histamine receptor antagonists in fluorescent imaging plate reader-based calcium assays","volume":"4","author":"Miller","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1124\/jpet.117.241596_bib44","first-page":"S5","article-title":"First-in-man study of ACT-541468, a novel dual orexin receptor antagonist: characterization of its pharmacokinetics, pharmacodynamics, safety and tolerability. In: American Society for Clinical Pharmacology and Therapeutics 2017 Annual Meeting Abstracts","volume":"101","author":"Muehlan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.117.241596_bib46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hup.980","article-title":"Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers","volume":"23","author":"Otmani","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1124\/jpet.117.241596_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"10.1124\/jpet.117.241596_bib48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fnins.2013.00254","article-title":"Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators","volume":"7","author":"Ramirez","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.117.241596_bib49","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.117.241596_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0167-0115(99)00076-2","article-title":"Orexins and orexin receptors: implication in feeding behavior","volume":"85","author":"Sakurai","year":"1999","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.117.241596_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.117.241596_bib52","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.bmcl.2015.03.035","article-title":"Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2","volume":"25","author":"Sifferlen","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.241596_bib53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.bmcl.2010.01.070","article-title":"Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists","volume":"20","author":"Sifferlen","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.241596_bib54","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.bmcl.2013.01.088","article-title":"Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1","volume":"23","author":"Sifferlen","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.241596_bib55","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"key":"10.1124\/jpet.117.241596_bib56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0269881115609015","article-title":"Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects","volume":"29","author":"Sun","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.117.241596_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5665\/sleep.5536","article-title":"Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys","volume":"39","author":"Tannenbaum","year":"2016","journal-title":"Sleep"},{"key":"10.1124\/jpet.117.241596_bib58","unstructured":"TGA (2014) Extract from the clinical evaluation report for suvorexant. Available at: www.tga.gov.au\/sites\/default\/files\/auspar-suvorexant-150411-cer.pdf. Accessed on: November 11, 2016. Australian Government, Department of Health, Therapeutic Goods Administration."},{"key":"10.1124\/jpet.117.241596_bib59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1124\/jpet.117.241596_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.117.241596_bib61","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"10.1124\/jpet.117.241596_bib62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/op400268f","article-title":"Catalytic asymmetric reduction of a 3,4-dihydroisoquinoline for the large-scale production of almorexant: hydrogenation or transfer hydrogenation?","volume":"17","author":"Verzijl","year":"2013","journal-title":"Org Process Res Dev"},{"key":"10.1124\/jpet.117.241596_bib65","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","article-title":"Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia","volume":"62","author":"Winrow","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.117.241596_bib66","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.241596_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152707779940754","article-title":"The prevalence, morbidities, and treatments of insomnia","volume":"6","author":"Zammit","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524196280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524196280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.241596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:57:17Z","timestamp":1739962637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524196280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0022356524196280"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.241596","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.241596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}